Osteoarthritis  >>  odanacatib (MK-0822)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
odanacatib (MK-0822) / Merck (MSD)
NCT00397683 / 2006-005956-34: A 52-Week Study to Assess the Effects of MK0822 on Knee Osteoarthritis (MK-0822-011)

Terminated
2
2
US, Europe, RoW
MK0822
Merck Sharp & Dohme LLC
Osteoarthritis
04/07
04/07

Download Options